Design Therapeutics Inc (DSGN) - Net Assets
Based on the latest financial reports, Design Therapeutics Inc (DSGN) has net assets worth $199.72 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($211.77 Million) and total liabilities ($12.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Design Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $199.72 Million |
| % of Total Assets | 94.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 0.97 |
Design Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore DSGN total assets for the complete picture of this company's asset base.
Annual Net Assets for Design Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Design Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see Design Therapeutics Inc (DSGN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $242.10 Million | -12.82% |
| 2023-12-31 | $277.69 Million | -15.16% |
| 2022-12-31 | $327.31 Million | -14.35% |
| 2021-12-31 | $382.13 Million | +3477.20% |
| 2020-12-31 | $-11.31 Million | -210.68% |
| 2019-12-31 | $-3.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Design Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22357100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $475.00K | 0.20% |
| Other Components | $468.83 Million | 193.65% |
| Total Equity | $242.10 Million | 100.00% |
Design Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Design Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Better Home & Finance Holding Company
NYSE:BETR
|
$430.66 Million |
|
Univanich Palm Oil Public Company Limited
BK:UVAN
|
$430.70 Million |
|
Albatron Technology Co Ltd
TWO:5386
|
$430.83 Million |
|
Mayville Engineering Co Inc
NYSE:MEC
|
$430.95 Million |
|
Movado Group Inc
NYSE:MOV
|
$430.48 Million |
|
Novavest Real Estate Ag
SW:NREN
|
$430.23 Million |
|
Prime Energy PE Ltd
TA:PRIM
|
$430.23 Million |
|
Samse SA
PA:SAMS
|
$430.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Design Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 277,687,000 to 242,097,000, a change of -35,590,000 (-12.8%).
- Net loss of 49,588,000 reduced equity.
- Share repurchases of 477,000 reduced equity.
- Other comprehensive income increased equity by 413,000.
- Other factors increased equity by 14,062,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.59 Million | -20.48% |
| Share Repurchases | $477.00K | -0.2% |
| Other Comprehensive Income | $413.00K | +0.17% |
| Other Changes | $14.06 Million | +5.81% |
| Total Change | $- | -12.82% |
Book Value vs Market Value Analysis
This analysis compares Design Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.13 | $13.30 | x |
| 2020-12-31 | $-0.42 | $13.30 | x |
| 2021-12-31 | $8.32 | $13.30 | x |
| 2022-12-31 | $5.88 | $13.30 | x |
| 2023-12-31 | $4.96 | $13.30 | x |
| 2024-12-31 | $4.28 | $13.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Design Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-20.48%) is below the historical average (-11.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -245.44% | 9.27x | 0.00x | $-1.68 Million |
| 2020 | 0.00% | -3663716.81% | 0.00x | 0.00x | $-7.15 Million |
| 2021 | -9.30% | 0.00% | 0.00x | 1.02x | $-73.75 Million |
| 2022 | -17.91% | 0.00% | 0.00x | 1.04x | $-91.35 Million |
| 2023 | -24.08% | 0.00% | 0.00x | 1.04x | $-94.63 Million |
| 2024 | -20.48% | 0.00% | 0.00x | 1.04x | $-73.80 Million |
Industry Comparison
This section compares Design Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Design Therapeutics Inc (DSGN) | $199.72 Million | 0.00% | 0.06x | $430.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more